SLGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sol-Gel Technologies Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 19, 2026
$64.98+0.73 (+1.14%)
Close on Oct 19, 2026
- Market cap
- $212.52M
- P/E (TTM)
- –
- Dividend yield
- –
Sol-Gel Technologies Ltd. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Sale of IP and license revenue [Member] | $18.60M | $9.80M | $380.00K | $0 | $7.50M | $0 | $0 | 95.9% | +89.9% |
| Royalties revenue [Member] | $707.00K | $1.62M | $1.17M | $3.88M | – | – | – | 3.6% | -56.3% |
| Support services [Member] | $82.00K | $126.00K | $0 | $0 | – | – | – | 0.4% | -34.9% |
| COLLABORATION REVENUES | – | – | $0 | $0 | $23.77M | $8.77M | $22.90M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $16.70M | $0 | $0 | – | – | – | – | 86.1% | – |
| Canada | $1.68M | $681.00K | $380.00K | $0 | – | – | – | 8.6% | +146.3% |
| Switzerland | $711.00K | $1.48M | $1.03M | $3.80M | – | – | – | 3.7% | -52.0% |
| Other [Member] | $278.00K | $691.00K | $147.00K | $80.00K | – | – | – | 1.4% | -59.8% |
| China | $27.00K | $4.87M | $0 | $0 | – | – | – | 0.1% | -99.4% |
| Israel | $0 | $3.81M | $0 | $0 | – | – | – | 0.0% | -100.0% |
From the segment and revenue-disaggregation notes of Sol-Gel Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.